Wall Street analysts predict that Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) will post ($0.89) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Entasis Therapeutics’ earnings. The business is expected to report its next earnings results on Tuesday, August 13th.
On average, analysts expect that Entasis Therapeutics will report full year earnings of ($3.39) per share for the current financial year. For the next financial year, analysts expect that the company will report earnings of ($2.45) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Entasis Therapeutics.
Entasis Therapeutics (NASDAQ:ETTX) last released its earnings results on Tuesday, May 14th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.24).
Several research firms have recently issued reports on ETTX. Wedbush restated an “outperform” rating and issued a $19.00 target price on shares of Entasis Therapeutics in a report on Tuesday, April 2nd. Zacks Investment Research lowered shares of GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a report on Monday, May 20th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $16.50.
An institutional investor recently bought a new position in Entasis Therapeutics stock. BlackRock Inc. acquired a new stake in Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 13,755 shares of the company’s stock, valued at approximately $56,000. BlackRock Inc. owned approximately 0.11% of Entasis Therapeutics at the end of the most recent quarter. 65.02% of the stock is currently owned by institutional investors and hedge funds.
Shares of Entasis Therapeutics stock traded down $0.03 during trading on Friday, hitting $6.32. The stock had a trading volume of 1,772 shares, compared to its average volume of 6,180. The company has a fifty day simple moving average of $6.25. The company has a current ratio of 8.79, a quick ratio of 8.79 and a debt-to-equity ratio of 0.02. Entasis Therapeutics has a 12 month low of $3.97 and a 12 month high of $13.70.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Recommended Story: What is a Futures Contract?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.